Loss-of-function germline mutations in the fumarase (FH) gene of the Krebs cycle characterize hereditary leiomyomatosis and renal cell cancer syndrome. Fumarase (FH) deficiency can be diagnosed by the loss of immunohistochemical expression. In this study, we investigated the occurrence and clinicopathologic features of FH-deficient uterine smooth muscle tumors (SMTs). A total of 1583 uterine and 157 nonuterine SMTs were examined using a polyclonal FH antibody and automated immunohistochemistry, and 86 uterine leiomyomas with an FH loss were identified. The frequencies of FH deficiency for subcohorts of uterine SMTs were 1.6% for unselected nonatypical leiomyomas, 1.8% for cellular leiomyomas, 37.3% for atypical leiomyomas, and 0% for leiomyosarcomas. One extrauterine, retroperitoneal estrogen receptor-positive leiomyoma was also FH deficient. The patient age of FH-deficient uterine leiomyomas was 20 to 52 years (median, 38 y). Grossly, these tumors were often soft and amorphous resembling a fibrothecoma. Histologically, the FHdeficient nonatypical leiomyomas lacked cellular packeting and distinct collagenous zones and showed chain-like or palisading nuclear arrangements, prominent staghorn-shaped blood vessels, oval nuclei with no or at most mild atypia, small eosinophilic nucleoli, and a low mitotic rate (0 to 1/10 HPF). The FHdeficient atypical leiomyomas had nuclear atypia often manifesting as multinucleation, prominent eosinophilic nucleoli, and mitotic activity up to 7/10 HPF, with atypical mitoses seen in 32% of cases. However, similar histologic changes were seen in some non-FH-deficient atypical leiomyomas. Loss-of-function FH-gene mutations including 5 whole-gene deletions and 3 frameshift mutations were identified in 8 of 16 FH-deficient nonatypical leiomyomas using multiplex ligation-dependent probe amplification and Sanger sequencing, respectively. Follow-up data on patients with FH-deficient atypical uterine leiomyomas revealed 19 patients alive (median follow-up 27 y) and 5 patients dead. Deaths occurred 9 to 30 years after surgery at a median age of 72 years; causes of death could not be determined. These results indicate that FH-deficient uterine leiomyomas occur with a high frequency among atypical leiomyomas and infrequently in nonatypical leiomyomas and are often histologically distinctive. They seem to have a low biological potential and lack any significant association with leiomyosarcoma.
B iallelic inactivation of the fumarase/fumarate hydratase (FH) gene that encodes tricarboxylic acid cycle enzyme fumarase (FH) characterizes tumors associated with hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome. In general, an underlying germline mutation combined with allelic imbalance at FH locus (1q43) in tumor tissue could be identified in affected individuals, characteristic of the classic Knudson hypothesis of inactivation of tumor-suppressor genes. This syndrome follows an autosomal-dominant pattern of inheritance. [1] [2] [3] [4] Individuals affected by FH-gene germline mutations are prone to a triad of tumors including multiple pilar leiomyomas of skin, early onset uterine leiomyomas, and renal cell carcinomas often showing papillary high-grade histology. Whereas most patients have leiomyomas, only 15% to 20% of them develop a kidney cancer. 1 Recurrent histologic patterns have been reported in uterine leiomyomas associated with the syndrome. These include increased cellularity, focal nuclear atypia including multinucleation, cells with prominent nucleoli, and cytoplasmic eosinophilic inclusions. Nonatypical examples have also been reported recently. [5] [6] [7] [8] Loss of FH protein in the renal carcinoma cells has been considered a diagnostic feature of HLRCC syndrome. [9] [10] [11] Immunohistochemical loss of FH has also been demonstrated in uterine and cutaneous leiomyomas. 7, 8, 12 However, more recently it has become apparent that FH loss could also be a somatic event in uterine leiomyomas and might not exclusively implicate the HLRCC syndrome. 8, 13, 14 In this study, we evaluated immunohistochemically a large number of tumors in the spectrum of uterine and other smooth muscle tumors (SMTs) for FH loss to better define the occurrence of FH losses in various uterine and other SMTs and also examine the histologic profile and prognosis of our patient cohort of FH-deficient uterine SMTs.
MATERIALS AND METHODS

Study Material
Histologically defined subcohorts of uterine SMTs (a total of 1583 cases) were immunohistochemically studied for FH expression. These groups were defined according to Bell et al. 15 They included: (1) atypical leiomyomas (n = 182), all of which had significant nuclear atypia but fell short of leiomyosarcoma by low mitotic activity (< 10/10 HPF, without having coagulative tumor necrosis). (2) Cellular leiomyomas (n = 57) were highly cellular, variably mitotically active spindle cell SMTs without significant nuclear atypia. (3) Epithelioid leiomyomas were SMTs with distinctly epithelioid cytology/epithelioid component (n = 61). (4) Leiomyosarcomas (n = 226) included 159 tumors with significant nuclear atypia and mitotic rate Z10/10 HPF. Another group (n = 67) was ascertained as leiomyosarcoma on the basis of significant nuclear atypia and presence coagulative tumor necrosis, despite mitotic activity <10/ 10 HPF. The above tumors were retrieved from the Armed Forces Institute of Pathology from 1970 to 1996. In addition, 1058 unselected, near-consecutive uterine leiomyomas (excluding only totally necrotic or calcified tumors) were collected from European and North American sources in the period from 2011 to 2015, examined grossly, and sampled for the study. These tumors contained only minor or focal atypia at the most. Selected categories of nonuterine SMTs included retroperitoneal estrogen receptor (ER)-positive leiomyoma in women (n = 40), angioleiomyoma (n = 33), glomus tumor (n = 23), and leiomyosarcoma of trunk or extremities (n = 30), and retroperitoneum (n = 31). Cutaneous leiomyomas were excluded from the study.
FH-deficient atypical leiomyomas were also histologically compared with non FH-deficient atypical leiomyomas. The presence of the following features was recorded: sharp versus infiltrative microscopic border, fascicle formation and packeting of fascicles by collagenous bands, staghorn vessels, cytoplasmic eosinophilic hyaline globules, enlarged eosinophilic nucleoli, mitotic rate per 10 HPF, and the presence of atypical mitoses.
Immunohistochemical Methods
All SMTs studied for FH expression were arranged in multitissue blocks each containing 30 to 65 cases. The sample size was estimated to exceed the size of a 0.6 mm 2 punch array sample by a factor of 5 to 15.
The primary antibody was a polyclonal anti-FH antibody (GeneTex, # GTX109877, diluted 1:500). All immunostaining was performed with Leica Bond-Max automation. Application of primary antibody (30 min) was preceded by a high-pH epitope retrieval buffer (Leica ar9640 buffer) for 25 minutes. The primary antibody was incubated for 30 minutes, polymer for 15 minutes, and postpolymer for 15 minutes. The color was developed with diaminobenzidine, followed by a light hematoxylin counterstain.
FH immunohistochemistry was initially evaluated with 18 specimens from known hereditary leiomyomatosis and renal cancer (HLRCC) syndrome patients. These included 7 uterine leiomyomas and 11 renal cell cancers, all of which demonstrated immunohistochemical loss of FH expression tumor cells with retention of expression in non-neoplastic components such as blood vessel walls, lymphoid cells, epithelia, and normal smooth muscle. In the subsequent study cases, FH deficiency was defined as the absence of staining in the tumor cells while observing positivity in the non-neoplastic elements.
Molecular Genetic Studies
Formalin-fixed paraffin-embedded tumor samples from nonatypical FH-deficient uterine leiomyomas (n = 16) were available for DNA extraction. Five to ten 5-mm-thick sections were deparaffinized with xylene, washed twice in ethanol, lyophilized, and incubated with proteinase K (10 mg/mL, Roche Diagnostics, Indianapolis, IN) in Hirt-Buffer at 551C for 24 hours. DNA was recovered using the Maxwell16 robotic system and DNA IQ Casework Pro Kit (Promega, Madison, WI).
Multiplex ligation-dependent probe amplification (MLPA) assay developed by MRC-Holland (Amsterdam, Netherlands) was used to evaluate the integrity of the FH gene. The reagents including SALSA MLPA probe mix for assessing losses in the FH gene, and MLPA protocol, were provided by the manufacturer. Data were analyzed with the Coffalyser.net software available online at http:// www.mlpa.com. MLPA ratios <0.7 defined the loss of a gene copy number (deletion), whereas Z0.7, <1.3, and Z1.3 defined normal or increased number of copies, respectively.
FH-gene coding sequences were polymerase chain reaction amplified with AmpliTaq Gold DNA polymerase (Applied Biosystems by Life Technologies, Austin, TX) using a standard 3-temperature protocol with denaturing at 941C, annealing at the primer-specific temperature and extension at 721C. The primer sequences, annealing temperatures, and sizes of amplicons are listed in the supplementary data (Supplementary Table 1 
RESULTS
The observed losses of FH immunostaining in uterine and selected other SMTs are summarized in Table 1 . The frequency of FH deficiency was highest in atypical uterine leiomyomas (37.3%), whereas it was similarly low, 1% to 2%, in conventional nonatypical and cellular spindle cell leiomyomas. None of the leiomyosarcomas showed FH deficiency. Images of FH loss in uterine SMTs are shown in Figure 1 .
The only FH-deficient extrauterine SMT was a retroperitoneal ER-positive, nonatypical leiomyoma in a woman. FH loss was not detected in any soft tissue angioleiomyomas, glomus tumors, or extrauterine leiomyosarcomas.
Clinical Features of FH-deficient Uterine SMTs
These tumors occurred in 86 women with an age range of 20 to 79 years (median age, 38 y). In few cases, history was notable beyond common leiomyoma symptoms by rapidly growing myomas (2 patients), and Meig syndrome with 3 L of ascites, and early hysterectomy in sister and mother at ages of 21 and 23 years, in 1 patients each. None of the patients had a history or family history of kidney cancer.
Hysterectomy was performed in 30 cases, myomectomies in 23 cases, and there was incomplete information in the remaining cases. Multiple leiomyomas were seen in 43 patients, there was a solitary leiomyoma removed in 23 cases, and no data on multiplicity in 21 cases. Many myomectomy specimens were morcellated not allowing to specify tumor size or multiplicity.
Follow-up data were available for 24 patients with FH-deficient atypical leiomyomas. Nineteen patients were alive 19 to 35 years after the procedure (median, 27 y) with no further information, and 5 patients were dead at 9 to 30 years after surgery at ages of 56 to 97 years (median, 72 y) with no further information on tumor status or cause of death.
Gross Pathology of FH-deficient Uterine SMTs
Commonly observed gross features included homogenous, white tumor tissue with a soft and amorphous texture without nodularity or whirling patterns typically seen in uterine leiomyomas, giving resemblance to a fibroma-fibrothecoma. The tumor size varied from <2 to 17 cm. Among cases with specified myoma size, there were 2 tumors <2 cm, 23 tumors 2 to 5 cm, 40 tumors 5 to 10 cm, and 11 tumors >10 cm.
Histopathology of FH-deficient Nonatypical Uterine Leiomyomas (n = 17)
Microscopic features in cases ascertained from randomly selected nonatypical leiomyomas included common lack of bundling of tumor cells by collagenous bands and absent or poorly developed fascicular ar-rangements. Characteristic features were higher cellularity than that typically seen in uterine leiomyomas and distinctive chain-like arrangements of tumor cells with oval nuclei set in a diffuse collagenous matrix ( Figs. 2A,  B ). Most cases contained at least some cells with mildly enlarged eosinophilic nucleoli (13/17), eosinophilic cytoplasmic inclusions (13/17), and staghorn vessels (17/ 17). One tumor had an appearance of cellular spindle cell leiomyoma containing vague nuclear palisading (Figs. 2C, D). Two cases each contained microcystic degeneration and infiltrative borders. Only mild, if any, nuclear atypia occurred so that none of these tumors were considered atypical leiomyomas. Mitotic activity was rare (0 to 1/10 HPF) with no atypical mitotic figures present.
Histopathology of FH-deficient Atypical Uterine Leiomyomas (n = 68)
Nuclear atypia was moderate in 62 cases and severe with pleomorphism in 6 cases. At least some nuclei contained eosinophilic nucleoli in most cases, sometimes with perinucleolar clearing (65/68). Multinucleation was common, often with wreath-like nuclear arrangements and nuclear pseudoinclusions (Figs. 3A-D). Mitotic activity varied 0 to 7/10 HPF (median, 1/10 HPF). Only 4 cases had mitotic rate >5/10 HPF (3 cases with 6 and 1 case with 7 mitoses) with atypical mitotic figures seen in 23 cases.
FH-deficient atypical leiomyomas often had a diffuse nonfascicular architecture (35/68) and even more often had a poorly defined fascicular pattern. They had a less prominent tendency for chain-like nuclear arrangements typically seen in the nonatypical FH-deficient leiomyomas. Eosinophilic globular cytoplasmic inclusions 
Histopathology of Non-FH-deficient Atypical Leiomyomas (n = 114)
In comparison, non-FH-deficient atypical leiomyomas less commonly lacked fascicular pattern (12/112) or contained eosinophilic cytoplasmic inclusions (21/110). Like the FH-deficient atypical leiomyomas, they also often, although less consistently, had staghorn vessels (45/ 113), prominent eosinophilic nucleoli (76/110) including macronuceoli, and perinucleolar halo-like clearing in some cases. Border was sometimes infiltrative (26/81); not all parameters could be evaluated in all cases.
Other FH-deficient SMTs (n = 2)
The only FH-deficient case in the epithelioid leiomyoma category was notable for an atypical keratin-positive epithelioid component comprising approximately 10% of the sample (Fig. 4) . FH deficiency was seen in leiomyoma cells but not in the epithelioid cells. The epithelioid cells were positive for keratins AE1/AE3, GATA3, and focally for gross cystic disease fluid protein and were interpreted most likely as a metastatic carcinoma of the breast involving the leiomyoma.
The only FH-deficient retroperitoneal leiomyoma was histologically similar to nonatypical FH-deficient leiomyomas showing poorly defined fascicular morphology with nuclear palisading and chain-like nuclear arrangements.
Immunohistochemistry of FH-deficient Uterine Leiomyomas
Immunohistochemically, FH-deficient leiomyomas were positive for smooth muscle actin, heavy caldesmon, and desmin, often showing cytoplasmic inclusions highlighted with the latter immunostain. ER positivity was typically seen in most cases, with occasional cases showing focally restricted pattern. All cases were negative for CD10. In comparison with non-FH-deficient conventional leiomyomas, the patterns of immunostains were similar, with the exception of FH loss.
Molecular Genetic Findings of FH-deficient Uterine Leiomyomas
Sixteen cases with available DNA were screened for FH alterations using MLPA and Sanger sequencing. Altogether 8 (50%) tumors were shown to have FH genetic alteration. There were 5 whole-gene deletions identified by MLPA and 3 frameshift mutations predicted to result in STOP codon formation detected by Sanger sequencing. The latter were in exon 4, c.567delA (p.E168Dfs*34) and exon 7, c.944_997delAA (p.K311Ifs*1) and c.1004_ 1005insC (p.A314Afs*5). Exon 
DISCUSSION
Germline mutations in the FH gene characterize HLRCC syndrome, which predisposes carriers to cutaneous and uterine SMTs and kidney cancer. The syndrome-associated tumors are FH deficient resulting from combination of germline and somatic loss-of-function mutations. These mutations vary from single nucleotide substitutions to whole-gene deletions. The most commonly reported are missense mutations, followed by frameshift, splice site mutations, and gene deletions. 2, 3, 13, 16 As a consequence, fumarate and succinate accumulate in the tumor cells, and this metabolic aber-ration is believed to be an oncogenic factor, for example, by stabilizing hypoxia-inducible factors causing their overexpression. [1] [2] [3] [4] Earlier studies evaluated the loss of FH indirectly by studying accumulation of succinylated proteins (succinylcysteine adducts). [9] [10] [11] Recently, antibodies to FH have become available opening a practical way to detect this abnormality. 7, 8, 12 This is analogous to detection of (SDH) deficiency in certain tumors, especially subsets of paragangliomas, gastrointestinal stromal tumors, and renal cancers. 17 In this study, we evaluated 1583 uterine and 157 nonuterine SMTs for FH expression using a specific antibody to identify FH-deficient tumors and subsequently study histopathology, FH gene mutations, and clinical correlation in such cases. We found FH deficiency with a high frequency in atypical leiomyomas (37%) and infrequent occurrence (0% to 2%) in nonatypical leiomyomas and leiomyosarcomas. One retroperitoneal ER-positive leiomyoma in a woman (2.5% of all retroperitoneal leiomyomas) was also FH deficient. As these extrauterine tumors are in many ways comparable to uterine leiomyomas, occurrence of FH deficiency also in this group is not very surprising.
In this study, 8 of 16 immunohistochemically FHdeficient tumors showed FH gene alterations. In 5 cases, deletion of the whole gene was detected by MLPA, and, in 3 cases, frameshift mutations were identified by Sanger sequencing. The latter occurred in exons 4 and 7, typical mutation "hot spots" in FH-deficient tumors. 2, 3, 16 Our frequency of FH mutations (50%) is similar to the one found in a recent study of immunohistochemically screened FH-deficient leiomyomas (6/10). This study also used massive parallel sequencing to supplement Sanger sequencing data but noted discordant results: additional mutations found but considered not definitively confirmed in the absence of ability to reproduce data by Sanger sequencing. 8 However, another study found all 5 FH-deficient leiomyomas to carry FH mutations. 7 Complexity of FH mutations is a major challenge in comprehensive detection requiring use of multiple techniques and access to high-quality DNA not always possible in archival specimens.
Although FH deficiency has been traditionally associated with the HLRCC syndrome, none of our patients had evidence for renal cancer, and only 1 patient had history of familial early-onset uterine leiomyomas suggestive for HLRCC. Similarly, a recent study identified 6 FH mutants among 10 FH-deficient uterine leiomyomas with none of the patients having a history of HLRCC syndrome. In addition, massive parallel sequencing data and Sanger sequencing of normal tissue suggested somatic nature of mutations in that study. 8 An earlier study searching for somatic FH mutations in uterine leiomyomas of nonsyndromic leiomyoma patients without immunohistochemical, but instead allelic loss screening, found such mutations in 2 of 166 tumors of 51 patients, a 1.2% frequency by leiomyoma count and 3.9% frequency by patient count. 13 The frequency obtained in the latter study cannot be compared with blind immunohistochemical screening studies. Another investigation failed to identify FH mutations in 7 sporadic leiomyomas with allele imbalance at 1q42-q43. 18 The mutation screening strategy used in the latter study could have contributed to the negative results.
On the basis of our study and previously reported studies, 8, 13 FH-deficient sporadic leiomyomas may carry mutations similar to the ones documented in HLRCC-related tumors, and these sporadic cases might contribute to the majority of FH-deficient leiomyomas found by screening studies, such as ours. Prospective clinical and combined germline and somatic genetic studies are needed to definitively determine how often FH-deficient leiomyomas are associated to the HLRCC syndrome. Apparent common somatic nature of FH deficiency in uterine leiomyomas would lessen the likelihood of association with HLRCC syndrome and diminish the impetus for compulsory germline studies and genetic counseling, unless there are clinical features to support this, such as familial occurrence of early-onset leiomyomas.
One could also consider epigenetic silencing as a potential mechanism for FH inactivation as known for SDH deficiency in 40% of SDH-deficient gastrointestinal stromal tumors. 19 However, one study found no epigenetic silencing for FH gene in FH-deficient tumors. 20 Atypical FH-deficient uterine leiomyomas had a set of histologic features including nuclear atypia, at least focally prominent eosinophilic nucleoli, staghorn vessels, prominent cytoplasmic eosinophilic inclusions, and common lack of fascicular morphology. Some of these features have been reported in previous studies on HLRCC syndrome-associated or, in some cases, FH-deficient sporadic uterine leiomyomas. [5] [6] [7] [8] However, when comparing with non-FH-deficient leiomyomas we observed similar features in non-FH-deficient atypical leiomyomas so that none of these features seem to be specific. Especially, prominent eosinophilic nucleoli, sometimes with perinucleolar halo-like clearing occurred in both FH-deficient and nondeficient leiomyomas, so that this feature is not specific for FH deficiency. Furthermore, perinucleolar clearing is difficult to define, and its presence may depend on histologic processing.
Illustrations of series of atypical uterine leiomyomas also highlight features similar to those seen in FH-deficient uterine leiomyomas also indicating that FH-deficient tumors form a large subset of those atypical leiomyomas. 21, 22 A recent study divided atypical uterine leiomyomas in types 1 and 2 suggesting that type 1 (seen in 53% of cases) corresponds to FH-deficient tumors because of morphologic similarity to previously reported atypical FH-deficient leiomyomas. However, FH expression was not studied in this investigation. 23 The nonatypical FH-deficient uterine leiomyomas also had a characteristic histology lacking bundling of smooth muscle cells around collagenous bands and a fascicular architecture. Additional distinct features are chain-like arrangement of nuclei (and tumors cells) and staghorn vessels. On the basis of our observations, FHdeficient tumors may also be tentatively identified by gross features as these tumors are often soft and lack whirling appearance typical of common uterine leiomyomas forming amorphous masses resembling fibromafibrothecoma tumors.
The biological potential of FH-deficient atypical uterine leiomyomas appears low on the basis of our direct and indirect evidence. There was no significant mortality in the patient cohort with follow-up, and most deaths were at old age and thus likely unrelated to the previous SMT. Also, there were no FH-deficient cases among the leiomyosarcomas neither defined by mitotic rate >10/ 10 HPF nor necrosis and lower mitotic rates, indicating that FH deficiency is rarely, if ever, associated with leiomyosarcoma. Therefore, FH deficiency could be a useful feature supporting a low biological potential of an atypical uterine SMT. Histologic features such as atypia, atypical mitoses, and infiltrative border do not seem to have malignant implications in the context of FH-deficient uterine SMTs.
In conclusion, we examined 1583 uterine SMTs immunohistochemically for FH loss and found 1.6% to 1.8% occurrence in unselected nonatypical leiomyomas and 37% frequency in atypical leiomyomas. FH-deficient tumors were often associated with FH mutations. Both follow-up data and inability to find FH-deficient tumors among leiomyosarcomas suggest low biological potential for FH-deficient uterine SMTs. Although many FH mutations in these leiomyomas are likely somatic, additional clinical and genetic studies are needed to determine how often FH-deficient leiomyomas are related to FH-germline mutations and the HLRCC syndrome.
